Addiction to methamphetamine is a significant public health problem, and there are currently
no pharmacological agents that are approved for the treatment of addiction to this powerful …

A variety of natural and synthetic agents have long been used for stimulant properties, with
nontherapeutic use producing multiple waves of stimulant abuse and dependence. The …

BACKGROUND: Several reports have shown that the glutamatergic system is involved in
both the pathogenesis of affective and stress-related disorders and in the action of …

Established treatments for obsessive-compulsive disorder (OCD) are of benefit in
approximately 3 of every 4 patients, but refractory disease remains distressingly common …

Craving and relapse are core symptoms of drug addiction and alcoholism. It is suggested
that, after chronic drug consumption, long-lasting neuroplastic changes within the …

There have been no recent advances in drug development for mood disorders in terms of
identifying drug targets that are mechanistically distinct from existing ones. As a result …

An increased understanding of the biological mechanisms underlying the process of
addiction has led to unique molecular targets and strategies for pharmacotherapies against …

Glutamate, a dicarboxylic amino acid, is the most abundantly active neurotransmitter in the
mammalian brain; it is also the principal excitatory neurotransmitter in the cerebral cortex. As …

There is a growing interest in the development of new pharmacological tools for treating
alcohol withdrawal and dependence. A number of anticonvulsants including valproate and …

Drug addiction is a chronic, relapsing brain disorder. Multiple neural networks in the brain
including the reward system (eg, the mesocorticolimbic system), the anti-reward/stress …